AIM
IMGN

Acrospire Investment Management’s Immunogen Inc IMGN Stock Holding History

Acrospire Investment Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-39,386
Closed -$80K – 2565
2016
Q4 		$80K Buy
+39,386
New +$79.1K 0.03% 1087

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's IMGN Position: Q1 2017 in Review

Acrospire Investment Management sold out of Immunogen Inc (IMGN) in Q1 2017, closing a stake of 39,386 shares — an estimated $80K sold.

Acrospire Investment Management first reported a position in IMGN in Q4 2016 and held it in 1 quarter. The position peaked at $80K in Q4 2016. 135 funds tracked by Wall St. Rank hold IMGN as of Q1 2017.

  • Acrospire Investment Management reported no remaining Immunogen Inc position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 39,386 Immunogen Inc shares in Q1 2017, an estimated $80K.
  • Acrospire Investment Management first reported a position in Immunogen Inc in Q4 2016 and held it in 1 quarter.
  • Acrospire Investment Management's Immunogen Inc position peaked at $80K in Q4 2016.
  • 135 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.